E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute myelocytic leukemia in remission (excluding relapse). CML: chronic myelocytic leukemia who are in the chronic phase of the disease. Severe aplastic anemia, hemoglobinopathies (thalassemia major). Inborn errors of metabolism. Myelodysplastic syndromes |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027703 |
E.1.2 | Term | Mismatched donor bone marrow transplantation therapy |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to evaluate the functioning of mesenchymal stem cells (MSC) in supporting hematopoietic cells transplantation (HSC). Cotransplantation of MSC with HSC may be beneficial by preventing rejection, decreasing graft-versus-host disease, enhancing engraftment and preventing tissue toxicity by chemoirradiation. GvDH incidence (acute grade II-IV GvDH) will be used as measure of efficacy.
|
|
E.2.2 | Secondary objectives of the trial |
1. Determination of time to neutrophil engraftment (>0.5 x 10E9/l). 2. Determination of time to platelet engraftment (>30 x 10E9/l). 3. Platelet level at day 30 post transplant. 4. Transfusions during first 30 days. 5. Incidence of chronic GvHD. 6. Treatment-related mortality (causes of death). 7. Overall relapse rate. 8. Survival. 9. Disease-free survival. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patient inclusion criteria 1. Informed consent.
2. Patients/subjects are required to meet the following inclusion criteria: a. Hematological disorders of the following types: ALL: patients with acute lymphoblastic leukemia in CR (<5% blasts in marrow) up to and including third remission (excluding relapse), AML: patients with acute myelocytic leukemia in remission, CML: patients with chronic myelocytic leukemia who are in the chronic phase of the disease, Severe aplastic anemia, hemoglobinopathies (thalassemia major), inborn errors of metabolism. MDS b. Patients may have undergone myeloablative or reduced intensity conditioning regimen. c. Use of anti-thymocytes globulin (ATG) during conditioning, according to the routine at each center. Both arms must be treated identically at each center.
3. Adequate cardiac function. Left ventricular ejection fraction or megascan or echocardiography must be at least 40% of predicted.
4. Adequate pulmonary function as defined as no severe or symptomatic restrictive or obstructive lung disease. FEV-1 >50% of predicted and DLCO >50% of predicted.
5. Female patients are non-pregnant.
6 Patients must be HIV-1 and –2 antibody, HIV -1 antigen and hepatite A, B and C seronegatives.
7. Patients must have a Karnofsky score of =70.
8. Patients must have an HLA-A, -B and -DRß1 identical stem cell donor. (HLA typing according to the routine at each center).
9. Immunosuppression should consist of cyclosporine or tacrolimus combined with four doses of methotrexate. Methotrexate is given on day+1, 15 mg/m2 and 10 mg/m2 on days +3, +6 and +11 after transplantation. Cyclosporine or tacromilus dose is according to the routines at each center. Because acute GvHD is a primary endpoint, no other immunosuppression than cyclosporine combined with methotrexate will be allowed.
Donor inclusion criteria 1. MSC donor must be HIV, HB-s antigen, anti HBc and anti HCV negative.
2. Related haploidentical or HLA mismatched MSC donor willing to donate MSC
3. Signed informed consent.
4. Each center request either bone marrow or peripheral blood stem cells according to routine at each center. If the donor only accepts one type of donation, he/she may be included anyhow. |
|
E.4 | Principal exclusion criteria |
Patient exclusion criteria 1. Hematologic malignancies, of the following types a) ALL patients in relapse as defined by >5% blasts in the marrow and/or circulating blasts in the peripheral blood, b) AML patients in relapse as defined by >5% blasts in the marrow. c) AML/ALL CR4 or later. d) CML in accelerated phase or blast crisis. e) MDS > RAEB II.
2. Patient has active alcohol or substance abuse.
3. Patient has a medical condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient.
4. Patient needing hematopoietic stem cell transplantation within three weeks.
5. Patient with a history of hyper-sensitivity to penicillin
Donor exclusion criteria 1. Donor more than 65 years of age, or unhealthy.
2. Donor positive for HIV, HTLV, hepatitis Bs antigen, anti-HCV or anti- HBc. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To establish the efficacy of infusions of identical, haploidentical or mismatched related or unrelated MSC in matched unrelated donor allogeneic hematopoietic stem cell transplantation of patients with hematologic malignancies and inborn errors of metabolism. GvHD incidence (acute grade II-IV GvDH) will be used as measure of efficacy.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
This study may be terminated, if for the investigator, there is sufficient reasonable cause. Circumstances that may warrant termination include: Determination of unexpected, significant, or unacceptable risk to patients. Failure to enter patients at an acceptable rate. Insufficient adherence to protocol requirements. Insufficient complete and/or evaluable data. Protocol violation. Administrative decision. New data able to influence the willingness of the investigators to pursue the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |